Monitoring Tissue-Engineered Graft Oxygenation In Vivo by Fluorine-19 Magnetic Resonance Spectroscopy

Samuel A Stein¹, Bradley P Weegman¹, Thomas M Suszynski², Meri T Firpo³, Melanie L Graham², Klearchos K Papas⁴, and Michael Garwood¹

¹Radiology, University of Minnesota, Minneapolis, MN, United States, ²Surgery, University of Minnesota, Minneapolis, MN, United States, ³Medicine, University of Minnesota, Minneapolis, MN, United States, ⁴Surgery, University of Arizona, Tucson, AZ, United States

Purpose: Transplantation of tissue-engineered grafts (TEGs) has the potential to treat numerous debilitating diseases. Non-invasive monitoring of the oxygen partial pressure (pO₂) in TEGs is critically important because of the harmful effects of prolonged or even short-term exposure to hypoxia and anoxia. This monitoring is particularly important in the early post-transplant period (before revascularization) or if a TEG is immunoisolated (and does not revascularize). Additionally, in vivo tissue pO₂ measurements may enable detection of events that would alter oxygenation of a TEG such as fibrous capsule formation, vascularization, inflammation, or cell proliferation, as well as the estimation of cell or tissue viability¹. The spin relaxation mechanisms of some biocompatible fluorine compounds are very sensitive to dissolved oxygen (and temperature) and insensitive to other external factors². Fluorine-19 nuclear magnetic resonance spectroscopy (19F-MRS) can, therefore, be used to quantify the oxygenation status of a TEG. This pilot study evaluated the utility of 19F-MRS for the non-invasive measurement of in vivo pO₂ within macroencapsulated TEGs following implantation in the murine model.

Methods: TEGs were constructed by injecting an emulsion of perfluoro-15-crown-5-ether (PFCE) and porcine plasma into a 40-μL TheraCyte® immunoisolation device (TheraCyte, Inc. Laguna Hills, CA), which was then crosslinked using 5% v/v bovine thrombin solution. An image of the encapsulation device and the distribution of fluorine in the device are shown in Figure 1. A linear correlation between the spin-lattice relaxation rate (R₁) and oxygen concentration was established before implantation of a TEG (Figure 2), and this correlation was used to convert measurements of R₁ to local pO₂ within the TEG following implantation. Nine male Lewis rats were implanted with a TEG into a dorsal subcutaneous pocket and assigned to groups for serial evaluation of oxygen content in relation to implant day +1 (n=3), +8 (n=3), and +15 (n=3). On the day of evaluation, rats were anesthetized with inhalation isoflurane, stabilized at a core body temperature of 37 °C, and imaged using a 16.4 T horizontal-bore magnet (Agilent Technologies Santa Clara, CA). Then, 19F-MRS was performed using a single-loop surface coil and an inversion-recovery sequence was used to obtain the R₁ from the singlet PFCE resonance within the TEGs. R₁ measurements within the TEG were then converted to pO₂ values using the linear calibration. Following imaging, animals were promptly euthanized using CO₂ for device explant and gross evaluation.

Results: The mean pO₂ in the encapsulated TEG 1 day post-implantation was 69±22 mm Hg. The mean pO₂ fell over time to 16±3 mm Hg at 8 days post-implantation and 0±10 mm Hg at 15 days post-implantation (Figure 3).

Conclusion: These preliminary studies confirm that 19F-MRS can be used to non-invasively measure pO₂ in vivo within a macroencapsulated TEG. Preliminary data suggest that the encapsulated TEG becomes hypoxic 1 week post-implantation despite the oxygen permeable membrane and may require supplemental oxygenation to sustain cells and tissue. Future studies will attempt to correlate pO₂ measurements with changes in TEG viability and oxygenation both pre- and post-transplantation.

This research was supported by the Minnesota Lions Diabetes Foundation, the Schott Family Foundation, the Schulze Family Foundation, Giner Inc., JDRF 5-2013-141, and the following NIH grants: P41 RR08079, P41 EB015894, and S10 RR025031.

References:
